| Literature DB >> 20958231 |
Sham Mailankody1, Esther Mena, Constance M Yuan, Arun Balakumaran, W Michael Kuehl, Ola Landgren.
Abstract
Multiple myeloma (MM) is a malignant plasma cell dyscrasia localized in the bone marrow. Recent studies have shown that MM is preceded in virtually all cases by a premalignant state called monoclonal gammopathy of undetermined significance (MGUS). This review focuses on non-IgM MGUS and its progression to MM. Although certain clinical markers of MGUS progression have been identified, it currently is not possible to accurately determine individual risk of progression. This review focuses on the various biologic and molecular markers that could be used to determine the risk of MM progression. A better understanding of the pathogenesis will allow us to define the biological high-risk precursor disease and, ultimately, to develop early intervention strategies designed to delay and prevent full-blown MM.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20958231 PMCID: PMC7032041 DOI: 10.3109/10428194.2010.525725
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022